Skip to main content

Welcome to our new website. We’re still fine-tuning things. If you experience any issues or would like to provide feedback, please contact us.

Patrick
M.
Tarwater
,
PhD

Senior Scientist
Patrick Tarwater

Departmental Affiliations

Primary
Division
General Epidemiology and Methodology

Contact Info

111 Market Place, Room 1026
Baltimore
Maryland
21202
US        

Research Interests

Biostatistics; Epidemiologic Methods; Survival Analysis; Longitudinal Data Analysis
Experiences & Accomplishments
Education
PhD
The University of Texas Health Science Center at Houston
1999
MS
Texas Tech University
1992
BA
Texas Tech University
1990
Overview
Dr. Tarwater began his career at the Bloomberg School of Public Health as an assistant research professor in the Department of Epidemiology – working in the Center for Analysis and Management of MACS Data (CAMACS). Dr. Tarwater's research included developing applications of bivariate processes and nonlinear models for characterization of trajectories of immunologic markers over time within disease processes. Since 2000, his collaborations with investigators at the Retrovirus Laboratory in Hopkins School of Medicine, and investigators at the Department of Infectious Disease and Microbiology at Pittsburgh Graduate School of Public Health, have led to productive research, science, and funding. In addition, Dr. Tarwater designed, implemented, and directed the first biostatistics and epidemiology consulting laboratory at the Texas Tech University system. During his 16 years in El Paso at the UTHealth School of Public Health and The Texas Tech School of Medicine he collaborated, educated, and mentored hundreds of clinical and health science investigators as well as students. Tarwater has taught in the Bloomberg Biostatistics and Epidemiology Summer/Winter Institutes since 2002.
Select Publications
Publications of primary and collaborative research:
  • Tarwater PM, Mellors J, Gore ME, Margolick J, Phair J, Detels R, and Muñoz A Methods to assess population effectiveness of therapies in HIV incident and prevalent cohorts. Am J Epidemiol 2001; 154:675-681.
  • Tarwater PM, Margolick J, Jin J, Phair J, Detels R, Rinaldo C, Giorgi J, and Muñoz A. Increase and plateau of CD4 T cell counts in the 3 ½ years following initiation of potent antiretroviral therapy. J Acquir Immune Defic Syndr 2001;27:168-175
  • Zink MC, Uhrlaub J, DeWitt J, Voelker T, Bullock B, Mankowski J, Tarwater PM, Clements JE, Barber S. Neuroprotective and anti–human immunodeficiency virus activity of minocycline. JAMA 2005;293(16):2003-2011
  • Makley MJ, English J, Drubach DA, Kreuz AJ, and Tarwater PM. Prevalence of Sleep Disturbance in Closed Head Injury Patients on a Rehabilitation Unit. Neurorehabil Neural Repair 2008;22(4):341-347.
  • Walker-Sperling VE, Pohlmeyer CW, Tarwater PM, Blankson JN. The effect of latency reversal agents on primary CD8+ T cells: implications for shock and kill strategies for human immunodeficiency virus eradication. EBioMedicine 2016; 8:217-229.